Filing Flows › Lipocine (LPCN) › Q3 2025
Lipocine (LPCN) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Lipocine (LPCN) reported revenue of $115K for the third quarter 2025 (Q3 2025) and -82% from the quarter before.
Lipocine, Q3 2025: revenue $115K, net loss $3.2M, operating cash flow −$3.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $115K | -82% | — |
| Operating profit | −$3.4M | — | — |
| Net earnings | −$3.2M | — | — |
| Operating cash flow | −$3.0M | — | — |
What changed
Revenue was $115K in Q3 2025, down 82% from the previous quarter.
Operating costs exceeded revenue by $3.4M, an operating margin of -2933.5%. The quarter ended with a net loss of $3.2M, wider than the previous quarter's $2.2M loss.
Operating cash flow was −$3.0M. Non-cash charges added back $14K of depreciation and amortization and $53K of share-based compensation.
Questions
What was Lipocine's revenue in the third quarter 2025?
Lipocine (LPCN) reported revenue of $115K for the third quarter 2025 (Q3 2025) and -82% from the quarter before.
Source: Lipocine 10-Q on SEC EDGAR.